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Abstract
Purpose Preparation of parenteral medication in hospitals is a complex process with a risk of microbial contamination of the
product, especially when inappropriately prepared. Contaminated parenteral medications can cause severe complications to
patients and increase morbidity in hospitals. The aim of this literature review is to systematically evaluate the contamination
rate of parenteral medications in hospitals prepared in a pharmacy environment and a clinical environment.
Methods A literature search of PubMed and EMBASE from 2000 to 2018 was performed. Two different environments where
preparation may be carried out were defined. Point estimates and 95% confidence intervals for contamination rates were
calculated for each environment of medication preparation. The meta-analysis was performed using a random effects model.
Results The contamination rates in the clinical environment (n = 13 studies) varied between 1.09 and 20.70%. In the pharmacy
environment (n = 5), all contamination rates were 0.00% except for one study (0.66%). The point estimates (random effect
model) for the overall contamination rate of doses prepared in the clinical environment was 7.47% (5.16–9.79%), and 0.08%
for doses prepared in the pharmacy environment. The point estimates (random effect model) for the overall contamination rate of
doses prepared by nursing/ medical staff was 7.85% (5.18–10.53%), and 0.08% for doses prepared by pharmacy staff.
Conclusions Significantly higher contamination rates were found for the preparation of parenteral medication in the clinical
environment compared to pharmacy environment. In accordance with recent guidance, the almost 100-fold higher changes of
contamination when reconstitution is performed in the clinical environment should urge hospitals to review their reconstitution
process and apply risk-reducing measures to improve patient safety of parenteral therapy.
Keywords Microbial contamination .Medication preparation . Pharmacy . Hospital
Introduction
Healthcare-associated infections are an important cause of
morbidity and mortality in hospitals all over the world [1].
Parenteral administration of (liquid) medications bears the risk
of nosocomial infections [2–4]. One of the sources of infec-
tions can be contaminated parenteral products [5, 6].
Contamination may occur at any step in the process from
manufacturing in industry or pharmacy to administration to
patients in the ward environment. Many parenteral products
require preparation steps including reconstitution of the med-
ication prior to administration. The highest contamination
risks have been associated with these preparation steps in the
hospital environment [7]. There are numerous case reports of
outbreaks [8–11].
This review will focus on the difference in contamination
risk of the reconstitution of parenteral medications between
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clinical and pharmacy environment. Parenteral products can
be reconstituted in the pharmacy department (pharmacy envi-
ronment) or in the clinical environment such as hospital
wards. In Europe, medication preparation in the pharmacy
department is performed according to good manufacturing
practice (GMP) guidelines or the recently adopted resolution
CM/Res AP (2011) on quality and safety assurance require-
ments for medicinal products prepared in pharmacies with a
special paragraph about reconstitution [12, 13]. For prepara-
tions on the wards, a general European guideline has been
published recently, but has not been evaluated in studies
[14]. Furthermore, several countries have published national
guidelines, such as the Dutch Hospital Patient Safety Program
or the epic-3 guideline for the UK [15, 16]. In a meta-analysis,
Austin et al. found a contamination rate of 3.7% for the clin-
ical environment and 0.5% for the pharmacy environment
[17]. Austin et al. included 34 studies, but 22 (65%) of those
were published before 2000. Due to new guidelines, and a
potentially changed working environment and infrastructure
in hospitals over the past 18 years an update of this systematic
review is needed to reflect current practice [15, 16, 18, 19].
This systematic review aims to establish and compare the
contamination rate of parenteral medications prepared in a
clinical environment and a pharmacy environment.
Literature search method
Search strategy
We followed the preferred reporting items for systematic re-
views and meta-analyses (PRISMA) statement in reporting
results of this systematic review [20]. The literature search
was conducted on 26 October 2018 in PubMed and
EMBASE.
We used the Emtree terms Bin t ravenous drug
administration^ (including synonyms), Bsyringes,^ ‘infusion’
in combinat ion with Bcontaminat ion^ or ‘ fungal
contamination.^All search terms were also used as free search
terms mentioned in the abstract or title of the study. An exam-
ple of the search strategy is added as Appendix.
Inclusion criteria
All original studies assessing contamination in relation to the
preparation of medication in the hospital setting were includ-
ed. The preparation of the medication includes all necessary
steps/manipulations needed to enable the use or administra-
tion of parenteral medication, e.g., the reconstitution of a par-
enteral medication product [14]. Studies had to report a con-
tamination rate or contaminated subjects as outcome.
Exclusion criteria
Case reports or studies about surface contamination, cytotoxic
drugs, and parenteral nutrition or lipid emulsions were excluded.
Those preparations were excluded as most hospitals operate sep-
arate procedures due to the toxic nature of cytotoxics and the
high susceptibility of contamination and bacterial growth of par-
enteral nutrition and lipid emulsions. Studieswhich only assessed
multidose vials or ampoules or infusion bags that were usedmore
than once were also excluded because they are intrinsically more
susceptible for contamination.
The search was limited to publications in English.
Furthermore, the search was limited to recent studies, because
improvements have been carried out over the past decades
concerning infection control and hygiene in the hospital set-
ting [15, 16, 18, 19]. Studies published between January 2000
and October 2018 were included in the analysis.
Data extraction
Two reviewers screened the titles and abstracts of the retrieved
records, independently [21]. Full texts of all potentially eligi-
ble records were also examined independently by the two
reviewers. Disagreements were resolved by consensus.
The following data were extracted using an Excel spread-
sheet: first author, publication year, country, sample tested,
method of contamination testing, environment of preparation,
type of personnel who performed the preparation, number of
simulations/preparations, and number of contaminated
containers/contamination rate.
The included studies were firstly categorized by environment
where the preparation was performed; pharmacy (controlled en-
vironment, e.g., cleanroom, laminar airflow hood (LAF)) versus
clinical environment. The clinical environment includes patient
care areas like the operating room, intensive care unit, and gen-
eral wards. And secondly, by the personnel who performed the
preparation: pharmaceutical personnel versus nursing/medical
staff. For each study, the number of microbially contaminated
and not contaminated doses was extracted.
Data synthesis and analysis
Point estimates and 95% confidence intervals for contamination
rates were calculated for each group. Unpaired t test was used in
the analysis. The meta-analysis was undertaken using a random
effects model [21]. When zero rates of contamination were re-
ported in the studies, meta-analysis was performed using a value
of 0.5 contamination in the study to overcome the mathematical
difficulties associated with logarithmic transformation. The ran-
dom effects model was chosen because of the variability of sam-
ple characteristics, intervention, and comparison conditions.
Heterogeneity of the studies was assessed using I2 test. A p value
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of < 0.05 was considered to be statistically significant. Data anal-
ysis was done in Microsoft Excel [22].
Results
Initially, a total of 2244 studies were identified for inclusion in
the systematic review. After screening of title and abstract,
2164 articles were discarded, because they did not meet the
selection criteria. The full text of the 82 remaining articles was
reviewed inmore detail. Finally, sixteen articles were included
in the systematic review (Fig. 1) [8, 23–37].
All studies were performed between 1999 and 2016. The
main characteristics of the included studies are summarized in
Table 1. Three studies compared directly the preparation of sy-
ringes in different environments: clinical versus pharmacy
(controlled) environment [28, 33, 35]. Ten studies were per-
formed in a clinical environment (general ward, operating room,
or intensive care unit) [8, 23–27, 29, 30, 32, 34] and three studies
were performed in a pharmacy environment) [31, 36, 37].
Six studies used a direct medium filled simulation tech-
nique for assessing microbial contamination [23, 28, 31,
35–37]. Eight studies examined microbial growth by an indi-
rect method taking samples from used vials, infusion bags, or
syringes [8, 24, 30, 32–34]. In two studies, the simulation was
performed using filter membrane units which were cultured
after use [26, 27].
Fifteen studies used a defined growth medium and incuba-
tion time and period to assess microbial growth. Microbial
contamination was assessed using visual inspection (turbidi-
ty). Only the study of Bertoglio et al. used frequency of re-
ported infection rate as primary outcome instead of microbial
contamination of the used syringes [25]. Seven studies made a
further examination of the microbial contamination with gram
staining and or identification of the microorganism [8, 24, 26,
28, 29, 32, 34].
Contamination rate
In the clinical environment, contamination rates varied between
1.09 and 20.70%. In the pharmacy environment, all contami-
nation rates were 0.00% except for the study of Trissel et al.,
they found a contamination rate of 0.66% (Fig. 2).
The point estimates (random effect model) for the overall
contamination rate of doses prepared in the clinical environ-
ment was 7.47% (5.16–9.79%), and 0.08% for doses prepared
in the pharmacy environment (Fig. 2). The calculated overall
contamination rate for the pharmacy environment was differ-
ent from the individual contamination rates of the included
studies, because we had to assume a 0.5 contamination rate
for studies were no contamination was found (see Method
section) [31, 33, 35, 36]. This had a major impact to the study
of Khalili et al. due to the small sample size (n = 17) [33].
The contamination rates of doses prepared in a clinical
environment were higher and more variable than those pre-
pared in a pharmacy environment. The heterogeneity of the
studies, expressed as I2 reflected this. I2 was 96% for the
clinical environment and 0.0% for the pharmacy environment.
Only two studies examined both environments and found
lower contamination rates for the pharmacy environment [33,
35]. All other studies examined only one environment.
Similar results were obtained in the second analysis by type
of personnel who performed the preparation of the doses. The
point estimates (random effect model) for the overall contam-
ination rate of doses prepared by nursing/medical staff was
7.85% (5.18–10.53%), and 0.08% for doses prepared by phar-
macy staff (Fig. 3).
Discussion
Our meta-analysis showed that about 1 in 13 parenteral products
prepared in a clinical environment were contaminated versus
about 1 in 1250 prepared in a pharmacy environment. Similar
82 articles full text analysis 
2244 records retrieved by literature search
66 excluded:
- Reuse of equipment/ 
multidose (7)
- Contamination/ modification 
of catheter/ infusion set (9)
- Parenteral nutrition (6)
- Case report (15)
- Risk modeling (1)
- Other; lack of relevance, 
lack of relevant data (29)
16 articles included in review
screening title and abstract 2164 excluded
Fig. 1 Flowchart summarizing
study selection
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results were obtained for nursing/medical staff versus pharmacy
staff. Remarkably, the systematic review by Austin et al., taking
into account studies dating back to the 1970s of the last century
found a lower contamination rate in the clinical environment.
This is surprising, given the attention, parenteral preparations
had in recent years and the availability of guidelines for proce-
dures in clinical environment [12, 14, 15]. High workload of
nursing staff may play a role. For example, it has been shown
that disruptions during the reconstitution affect aseptic technique
[38, 39]. Also, the preparation and administration of parenteral
medication is a multi-step process which is time consuming
when performed properly [40]. The observed increase in contam-
ination could also be due to the fact that currently more products
are being supplied as ready-to-use or ready to administer, having
95% CI
Study Rate Lower limit Upper limit
Austin, 2013 2,44 1,34 3,54
Baniasadie, 2013 5,37 3,12 7,61
Gargiulo, 2012 6,45 3,07 9,83
Gargiulo, 2016 2,86 2,22 3,51
Heid, 2016 20,70 16,08 25,32
Henein, 2013 1,92 -0,74 4,59
Kerenyi, 2011 16,13 9,81 22,45
Khalili, 2013 1,09 -1,04 3,22
Macias, 2010 2,08 0,64 3,53
Mahida, 2015 15,02 11,34 18,70
van Grafhorst, 2002 19,33 16,19 22,48
Effect summary; Nursing/ 7,85 5,18 10,53
                          medical staff
Austin, 2013 0,10 -0,18 0,38
Kaestli, 2012 0,13 -0,22 0,47
Khalili, 2013 2,94 -5,21 11,09
Stucki, 2009 0,10 -0,18 0,38
Trissel, 2003 0,05 -0,09 0,18
Trissel, 2007 0,66 0,01 1,30
van Grafhorst, 2002 0,50 -0,48 1,48
Effect summary; Pharmacy staff 0,08 -0,02 0,17
Contamination rate
-10 0 10 20 30
Figure 3 Summary of
contamination rates of doses
prepared by nursing/medical staff
(upper part) and pharmacy staff
(lower part)
95% CI
Study Rate Lower limit Upper limit
Austin, 2013 2,44 1,34 3,54
Baniasadie, 2013 5,37 3,12 7,61
Bertoglio, 2013 4,04 2,57 5,51
Gargiulo, 2012 6,45 3,07 9,83
Gargiulo, 2016 2,86 2,22 3,51
Heid, 2016 20,70 16,08 25,32
Henein, 2013 1,92 -0,74 4,59
Kerenyi, 2011 16,13 9,81 22,45
Khalili, 2013 1,09 -1,04 3,22
Macias, 2010 2,08 0,64 3,53
Mahida, 2015 15,02 11,34 18,70
Stucki, 2009 11,00 8,94 13,06
van Grafhorst, 2002 15,37 12,88 17,86
7,47 5,15 9,79
Kaestli, 2012 0,13 -0,22 0,47
Khalili, 2013 2,94 -5,21 11,09
Stucki, 2009 0,10 -0,18 0,38
Trissel, 2003 0,05 -0,09 0,18
Trissel, 2007 0,66 0,01 1,30
0,08 0,00 0,00
Contamination rate
Effect summary; clinical 
environment
Effect summary; pharmacy 
environment
-10 0 10 20 30
Fig. 2 Summary of
contamination rates in clinical
environment (upper part) and
pharmacy environment (lower 5
references)
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a deskilling effect on the staff on a ward [14, 18]. Austin et al.,
found a slightly higher contamination rate for the pharmacy en-
vironment [17]. This trend is reassuring and may be the effect of
the more stringent guidelines and stricter adherence to microbial
monitoring in clean room areas nowadays [12, 14].
Inmost of the studies, the type of environment determined the
type of staff carrying out the preparation. Methodologically, it is
therefore difficult to distinguish between the effects of the envi-
ronment and the type of staff on the contamination rate. A few
studies suggest that personnel has a major impact. The studies by
Grafhorst et al. and Austin et al. found a zero contamination rate
when pharmacy staff prepared medication in a clinical environ-
ment [23, 28]. Also, the study by Thomas et al. suggested that the
type of staff is probably by far the most deterministic factor
determining contamination rate. In the study of Thomas et al.,
no significant difference in the microbial growth of products
were seen; any environmental considerations were
overshadowed by the importance of the operator’s aseptic tech-
nique [23, 28, 41]. This may also be the reason for the higher
contamination rates seen in the clinical environment in our re-
sults. Good aseptic technique includes hand hygiene, disinfecting
the preparation area, and vials. Some studies showed low adher-
ence to aseptic technique by medical staff in healthcare establish-
ments [38, 42–44]. Pharmacy staff receives extensive training on
aseptic techniques and their skills are validated regularly [12, 13].
There are considerable differences in the environment on the
ward compared to the pharmacy department. Nowadays, prepa-
ration areas in the pharmacy department are highly controlled
and require an appropriate environmental cleanliness level to
minimize the risks of particulate or microbial contamination
[12]. In contrast, by and large, clinical environments lack most
of those features which increases the risk for microbial contam-
ination of the preparation [12, 14].
Implications for practice
We lack large, well-conducted studies linking contamination
rates of parenteral products with patient outcomes between
different environments. Case reports have shown high mor-
bidity and mortality caused by contaminated medications
[8–10, 45]. Given the high costs of hospital-acquired infec-
tions [46–49], the high contamination rate associated with
parenteral products prepared in clinical environment seems
unacceptable. In the USA, the majority of intravenous doses
are prepared in the pharmacy department while in European
hospitals, parenteral medication are mostly prepared in near-
patient areas due to insufficient resources [50]. As already
mentioned, different guidelines exists for preparation of par-
enteral products in clinical environment across Europe. But
also to pharmacy preparations differences exists in practice
and legislation across Europe [51].
Recently, the Committee of Ministers of the Council of
Europe passed a Resolution CM/Res(2016)2 on good recon-
stitution practices in healthcare establishments for medicinal
products for parenteral use [14]. This resolution provides a
risk assessment for the reconstitution of medicinal products
which can help healthcare institutions to decide which prod-
ucts should be reconstituted in the pharmacy and which prod-
ucts may be safely reconstituted in clinical environment with
appropriate risk-reducing measures, like training and standard
operating procedures [14]. It also outlines the need to docu-
ment the qualification and competence (continuous education,
maintaining competence, regular training) of medical staff
performing preparations in clinical environment. Particularly
important are knowledge and skills in calculation, awareness
about hygiene and microbiology, and training in aseptic han-
dling to prevent errors during the preparation of medication
[14, 52, 53]. Another strategy to reduce the contamination rate
is the use of ready to use or ready to administer (RTU/RTA)
medication prepared by the pharmacy or industry as recom-
mended by the Joint Commission International standard [18].
Limitations
This systematic review has a number of limitations which need
to be considered. First, only two databases were used for the
literature search as we expected that these databases contained
the relevant literature. We also did not carry out a formal search
of gray literature. All references of the included studies were
reviewed but no new studies were found. Second, the diversity
of the included studies. The included studies used different
methods of sampling, different simulation methods and even
within one environment (either clinical or pharmacy) studies
were performed at truly different conditions. Not only clinical
environment and pharmacy environment, but also in different
clinical environments, e.g., operating room, intensive care unit,
and general ward. This is also shown in the heterogeneity of the
results of the studies about contamination rate in the clinical
environment (I2 = 96%). Further, subgroup analysis could not
be performed due to small subgroups. Although the I2 is very
high, the clinical implications of the observed degree of incon-
sistency across included studies should be considered [54]. All
estimates of the individual studies show more or less the same
direction of effect. Austin et al. found a similar heterogeneity
[17]. Due to the heterogeneity of the methods of the studies, we
did not perform a detailed assessment of the quality of the
studies. Also currently available instruments were not suitable
for the studies included in our review [55].
Third, all included studies used microbial contamination as
endpoint. But, the method of determining contamination var-
ied between the studies. Different methods of sampling were
used, different growth media were used, and incubation time
and incubation temperature of agar plates syringes were not
Eur J Clin Pharmacol (2019) 75:609–617 615
identical which could lead to different outcomes. Further, not
all studies characterized the microorganism in contaminated
products. Future studies should apply standard procedures
with minor manipulations to obtain samples following
established standards in testing samples (European
Pharmacopeia or United States Pharmacopeia (USP)).
Finally, more work needs to be done to address the clinical
implications of contaminated medications. This is an impor-
tant aspect of patient safety of parenteral products and it
should be aligned with other initiatives such as good prescrib-
ing [56], safe labelling [57], and technologies to improve the
administration of medications, for example, a bar-code admin-
istration system [58, 59].
Conclusion
Significantly higher contamination rates were found for the
preparation of parenteral medications in the clinical environ-
ment compared to pharmacy environment. In accordance with
the recent guidance, hospitals should review the reconstitution
process and apply risk-reducing measures to improve patient
safety of parenteral therapy.
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